Clinical Trial Update: The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating the effect of PCSK-9 inhibition on PET-derived coronary flow reserve in patients with stable coronary artery disease at hig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stable Coronary Artery Disease

Drugs mentioned

• PCSK-9 inhibitor

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Stable Coronary Disease | Phase 4 | Status: RECRUITING